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A non-randomised pilot study of the
Solutions for Medication Adherence
Problems (S-MAP) intervention in
community pharmacies to support older
adults adhere to multiple medications
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and C. M. Hughes1*
Abstract
Background: Older patients prescribed multiple medications commonly experience difficulties with adherence.
High-quality evidence on interventions targeting older patients is lacking. Theory is rarely used to tailor adherence
solutions. This study aimed to pilot test a novel intervention, developed using the Theoretical Domains Framework,
which guides community pharmacists in identifying adherence barriers and delivering tailored solutions (behaviour
change techniques). Key study procedures (e.g. recruitment, data collection) for a future randomised controlled trial
(cRCT) were also assessed.
Methods: Using purposive sampling, this non-randomised pilot study aimed to recruit 12 community pharmacies
(six in Northern Ireland; six in London, England). Pharmacists were trained to deliver the intervention to non-
adherent older patients (maximum 10 per pharmacy; target n = 60-120) aged ≥ 65 years (reduced to 50 years due
to recruitment challenges) and prescribed ≥ 4 regular medicines. The intervention, guided by an iPad web-
application, was delivered over 3-4 face-to-face or telephone sessions, tailored to specific barriers to adherence. We
assessed the feasibility of collecting adherence data (primary outcome: self-report and dispensing records), health-
related quality of life (HRQOL) and unplanned hospitalisations (secondary outcomes) at baseline and 6-months. The
final decision on progressing to a cRCT, using pre-defined ‘stop-amend-go’ criteria, is presented.
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Results: Fifteen pharmacists from 12 pharmacies were recruited and trained. One pharmacy subsequently dropped
out. Sixty patients were recruited (meeting the ‘Amend’ progression criteria), with 56 receiving the intervention.
Adherence barriers were identified for 55 patients (98%) and a wide range of behaviour change solutions delivered
(median: 5 per patient). Self-report and dispensing adherence data were available for 37 (61.7%) and 44 (73.3%)
patients, respectively. HRQOL data were available for 35 (58.3%) patients. GP-reported and self-reported
hospitalisations data were available for 47 (78.3%) and 23 (38.3%) patients, respectively. All progression concepts
were met (nine ‘Go’ and three ‘Amend’ criteria).
Conclusion: This study demonstrates the feasibility of key study procedures (e.g. pharmacy recruitment) and
delivery of a tailored adherence intervention in community pharmacies. However, modifications are required to
enhance issues identified with patient recruitment, retention and missing data. A future definitive cRCT will explore
the effectiveness of the intervention.
Trial registration: ISRCTN, ISRCTN73831533, Registered 12 January 2018.
Keywords: Medication adherence, Polypharmacy, Theory, Behaviour change, Community pharmacy, Pilot study,
Technology, Complex intervention
Key messages regarding feasibility
1) What uncertainties existed regarding feasibility?
 Uncertainties remained regarding the feasibility of
pharmacy sampling/recruitment, patient screening/
recruitment, intervention delivery and outcome data
collection procedures.
2) What are the key feasibility findings?
 This study has demonstrated the feasibility of
pharmacy sampling/recruitment procedures and
intervention delivery in the community pharmacy
setting. Challenges were identified with patient
recruitment procedures, patient retention and
missing data.
3) What are the implications of the feasibility findings
for design of the main trial?
 The findings from this study will inform changes
required to study procedures in the main trial
including modifications to reduce the amount of
missing data and enhance patient recruitment/
retention (e.g. support from a clinical research
network)
Background
Medication adherence, defined as taking medications in
accordance with the prescribers’ directions, can be prob-
lematic, particularly in older patients (≥ 65 years) pre-
scribed multiple medicines to treat a range of long-term
conditions [1]. A recent study in Ireland found that 31%
of older people living with multimorbidity (≥ 2 chronic
conditions) were non-adherent, with non-adherence
rates varying across conditions and treatments [2]. Poly-
pharmacy, commonly defined as the prescribing of four
or more medications, is associated with low adherence
[3]. Medication non-adherence has a negative impact on
both individual patients and the wider healthcare system
as it can result in inadequate disease control, decreased
quality of life, increased morbidity, hospitalisations and
increased healthcare costs [1, 4]. For example, a 2012 re-
port from the Institute for Healthcare Informatics esti-
mated that total costs from non-adherence amounted to
approximately US$270 billion per year globally [5].
To date, a plethora of interventions have been developed
to address the challenge of medication non-adherence in
adults, but these have shown only limited effectiveness in
improving adherence and clinical outcomes [6]. A recent
Cochrane review of adherence interventions, designed to
target older patients prescribed multiple medications, found
a lack of high-quality evidence on intervention effectiveness
and interventions were not commonly tailored to individual
patient-reported barriers to adherence [1]. It has been pro-
posed that psychological theories may guide the develop-
ment of more effective complex adherence interventions by
targeting causal determinants of behaviour [7]. However, a
systematic review of interventions targeting older patients
prescribed multiple medications found that theory was
rarely used to guide the intervention content [8].
The S-MAP (Solutions for Medication Adherence
Problems) intervention is a theory-based intervention
that has been systematically developed in line with the
United Kingdom (UK) Medical Research Council’s
(MRC) guidance for complex interventions [9]. The
intervention is tailored to each individual patient’s
underlying reasons for non-adherence. Using the Theor-
etical Domains Framework [10], previous research in-
volving focus groups with older patients identified eight
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key domains linked to non-adherence (beliefs about con-
sequences; motivation and goals; environmental context
and resources; knowledge; memory, attention and deci-
sion processes; social influences; behavioural regulation;
nature of the behaviours) [11]. These domains were then
mapped to 11 behaviour change techniques (BCTS)
using established mapping resources [12, 13] (e.g. infor-
mation about health consequences; prompts/cues; goal-
setting—behaviour). BCTs are ‘…the smallest compo-
nents of behaviour change interventions that on their
own in favourable circumstances can bring about
change’ [14]. The 11 BCTs identified using this system-
atic approach were then developed into an intervention
package for delivery by community pharmacists to older
patients prescribed multiple medications [15], and a pre-
liminary feasibility study was conducted in two commu-
nity pharmacies in Northern Ireland (NI) (https://doi.
org/10.1186/ISRCTN17966504) [16]. Although the inter-
vention showed potential, this study identified the need
for modification of the intervention and refining of study
procedures. For example, the original intervention in-
cluded a paper-based adherence assessment tool to iden-
tify adherence barriers and solutions (i.e. BCTs).
However, feedback from pharmacists indicated that large
amounts of paperwork would not be acceptable; hence,
an electronic version of the adherence assessment tool
warranted development and testing.
The current paper reports a multi-centre non-
randomised pilot study of an enhanced intervention (S-
MAP) conducted in community pharmacies in NI and
London, England. This pilot study, which contained an
intervention group only (with no control group), was de-
signed to examine important study procedures (e.g. pa-
tient recruitment) on a larger scale, in advance of a
larger cluster randomised controlled trial (cRCT) of the
S-MAP intervention.
The main objectives of the current study were as
follows:
1) Test approaches to sampling, recruitment and
retention of community pharmacies
2) Test approaches to screening, recruitment and
retention of patients in community pharmacies
3) Assess the delivery of the S-MAP intervention
(guided by an iPad web-application) in community
pharmacies in NI and London
4) Explore the feasibility of collecting data for
outcome assessment
The final decision on whether to proceed to a de-
finitive trial of effectiveness (cRCT), based on the
pre-defined progression (Stop-Amend-Go) criteria ori-
ginally outlined in the study protocol [17], is also
presented.
Methods
Study design and setting
A non-randomised multi-centre pilot study (intervention
only group, i.e. no control) was conducted in the com-
munity pharmacy setting in NI and London.
Sampling and recruitment of community pharmacies
The study aimed to recruit 12 community pharmacies
across NI and London with a view to 10 pharmacies
completing the study (i.e. assuming a retention rate of
80%). Using maximum variation sampling, the study
aimed to recruit six pharmacies in NI, with at least one
from each of the five Health and Social Care Trust areas
(HSCTs; the administrative areas for healthcare
provision in NI). In London, six Clinical Commissioning
Groups (CCGs) were purposively selected from 32 in the
region with the aim of recruiting one pharmacy from
each. CCGs from both inner and outer areas of London
were selected taking into consideration the level of
deprivation [i.e. Index of Multiple Deprivation (IMD)
CCG rank scores whereby a rank of 1 indicates the most
deprived CCG area, and a rank of 191 indicates the least
deprived CCG area] [18]. The selected CCGs (and ranks)
were Newham (11th), Lambeth (38th), Camden (94th),
Bromley (162nd), Barnet (138th) and Richmond (186th)
[18]. The 2019 England IMD decile [18] (most deprived
area = score of 1, least deprived area = score of 10) and
2017 NI Multiple Deprivation Measure [19] (MDM;
most deprived area = score of 1 and least deprived area
= score of 890) score for the location (i.e. postcode) of
each recruited community pharmacy in London and NI,
respectively, are presented in the “Results” section.
The study also aimed to include pharmacies in urban,
suburban and rural areas and different types/sizes of
pharmacies (independently-owned, small and large
chains). Region-specific definitions were used to categor-
ise the type of pharmacy as NI has relatively few chains
with more than 100 pharmacies, compared to England
(see Additional file 1 for definitions) [20, 21].
Letters seeking expressions of interest were mailed to
60 pharmacies in each region (12 per HSCT area in NI
and 10 per CCG in London). Pharmacies in the mailing
list were strategically selected to include a broad range
of pharmacy types, social deprivation levels and different
types of area (e.g. rural/urban). Members of the research
team (DP, EC) contacted pharmacists who returned
reply slips to discuss participation in the study. Those
who did not return reply slips were contacted via tele-
phone to enquire about participation. Non-responding
pharmacies were purposively selected and contacted to
provide maximum variation within the sample (e.g.
chains and independently-owned pharmacies). Commu-
nity pharmacies were eligible to participate if they had a
suitable consultation area (e.g. private area with seating),
Patton et al. Pilot and Feasibility Studies            (2021) 7:18 Page 3 of 21
access to Wi-Fi and printing facilities. Pharmacists were
eligible to participate if they worked on a regular basis in
the pharmacy (e.g. > 2 days per week). Pharmacy support
staff were also eligible for participation, to support phar-
macists with study procedures (e.g. patient recruitment).
Interested pharmacies were emailed/posted a study in-
formation sheet and consent form and meetings were ar-
ranged to discuss participation and obtain written
informed consent. Pharmacists were invited to attend a
1-day training workshop to equip them to deliver the
study. An online training package was developed, using
the Moodle® platform, which included a version for
pharmacists who were unable to attend the workshop
and a version for pharmacy support staff. Pharmacies
were provided an honorarium of £500(NI)/
£600(London) for participation in the study and each
pharmacist was awarded a certificate for their Continu-
ing Professional Development portfolio. Pharmacies
were also provided an additional £30 for each patient
they recruited into the study and delivered the interven-
tion to (up to an additional £300 per pharmacy).
Screening and recruitment of patients
Patients were eligible for participation in the study if
they were (1) 65 years or older (amended during the
study to 50 years, see below), (2) prescribed four or more
regular medications (polypharmacy), excluding ‘when re-
quired’ medicines or those with variable dosing direc-
tions (e.g. take once or twice daily), (3) receiving
prescriptions from the recruited pharmacy for at least
12 months, (4) identified as non-adherent (see below),
(5) living in their own home, (6) able to provide written
informed consent and (7) receiving all regular medica-
tions from the recruited pharmacy. Patients were ex-
cluded if they were prescribed medications for the
management of dementia as the intervention was not
designed to address the additional challenges faced by
this patient group.
Initially, a two-stage screening process was trialled. In
stage 1, pharmacists screened Patient Medication Re-
cords (PMR) or prescriptions to identify patients who
met eligibility criteria 1-3. Patients prescribed medica-
tions for dementia were excluded at this stage. In stage
2, patients who met criteria 1-3 were approached either
in the pharmacy or mailed a questionnaire to identify if
they were non-adherent (criterion 4), using two self-
report measures—Medication Adherence Report Scale
(MARS)-5 [22] and a single item adapted from Lu et al.
[23]. Total scores for MARS-5 (‘Always’ = 1; ‘Often’ = 2;
‘Sometimes’ = 3; ‘Rarely’ = 4; ‘Never’ = 5) range from 5
to 25 with higher scores denoting higher adherence. The
Lu item was scored from 0 to 100% (‘Very poor’ = 0%;
‘Poor’ = 20%; ‘Fair’ = 40%; ‘Good’ = 60%, ‘Very good’ =
80%, ‘Excellent’ = 100%) [23]. Patients who scored < 80%
on the Lu item and/or < 25 on MARS-5 were deemed
non-adherent. The cut-off point for the Lu item is in
line with the 80% cut-off commonly used in adherence
research [24, 25]. The cut-off point of < 25 for MARS-5
has been used previously in the literature [26, 27]. The
pharmacist also confirmed that the patient met criteria
5-7 in stage 2. Eligible patients were invited to take part
and written informed consent was obtained by the
pharmacist or trained support staff member prior to ses-
sion 1 (see ‘Intervention overview’ section).
Due to challenges with patient recruitment observed
during the first 4 months of the study, the screening ap-
proach was modified. Based on pharmacist feedback, pa-
tients did not always report non-adherence on the
questionnaire despite dispensing records highlighting
potential problems. Following an approved amendment
to the study protocol, the self-report adherence ques-
tionnaire was removed from the eligibility screening
process. The questionnaire was, however, still adminis-
tered as part of the baseline outcome assessment follow-
ing recruitment (see ‘Outcome data collection’ section).
In the modified screening approach, an assessment of
the patient’s adherence was made based on informal dis-
cussions between the patient and pharmacist and/or in-
formation obtained from dispensing records (e.g.
medication supply gaps). Information flyers were also
distributed in the pharmacy and posters displayed to ad-
vertise the study and enhance recruitment rates. Add-
itionally, as suggested by the pharmacists, to improve
recruitment rates the age limit for participation was low-
ered from 65 to 50 years. Initially, a period of 6 months
was assigned for patient recruitment, however, due to
the challenges experienced this was extended to 12
months to allow for an assessment of the modifications
made. Collection of outcome data was originally planned
to take place at baseline, 6 months and 12months from
baseline, but due to the extended recruitment period,
the 12-month follow-up time point was removed.
Sample size
As this was a pilot study that did not aim to assess
intervention effectiveness against statistical criteria, a
power calculation was not conducted. Instead, in an-
ticipation of a future cluster RCT, a pragmatic target
of 10 patients per community pharmacy (i.e. a max-
imum of 120 patients in total) was used for this
study. A minimum of 60 patients was deemed suffi-
cient to meet the ‘Amend’ progression criterion for
patient recruitment (see ‘Progression criteria’). Based
on the experience of the research team, this sample
size coupled with the sampling approach outlined
above would provide sufficient data to meet the ob-
jectives of this pilot study.
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Retention of patient participants
Retention rates were determined based on the propor-
tion of retained participants who were assessed with
valid primary outcome data [28]. Patients were consid-
ered retained in the study if they had data suitable for
analysis for the primary outcome of medication adher-
ence (see ‘Outcome data collection’ section).
Intervention overview
The S-MAP intervention is an individually tailored
medication adherence intervention that was designed for
delivery by community pharmacists and guided by a
web-application (hereafter referred to as an ‘app’), which
contained an adherence assessment tool. Each pharma-
cist was provided with individual log-in details and an
iPad to access the app during the study (to allow ses-
sions to be conducted in consultation rooms/areas with-
out computer equipment). Each recruited patient was
entered into the system using a unique study identifica-
tion number. The patient’s medications were manually
recorded on the app in advance of their first session and
the medication history confirmed with the patient at
Session 1 and their general practitioner (GP) if required
(e.g. to confirm the correct dosage).
Intervention content (behaviour change techniques)
As reported in the protocol paper [17], the intervention
content (BCTs) in the app was coded and compared to
the intervention content in the previous paper-based
version. The purpose was to ensure all anticipated BCTs
were present in the app-supported version of the inter-
vention and to identify any additional, unanticipated
BCTs. This BCT coding exercise was undertaken by
members of the research team (SC, CC, JF, EC) who
were not directly involved in the original content devel-
opment. Four additional BCTs were identified during
this process and were added to the intervention specifi-
cation, bringing the total number of BCTs to 15. The
final version of the S-MAP app tested in the current
study was also coded for BCTs and one further BCT was
identified (the ‘Instruction on how to perform the behav-
iour’ section) [29]. This brings the total number of BCTs
in the app to 16 (see Additional file 2): (1) problem solv-
ing, (2) self-monitoring (behaviour), (3) feedback on be-
haviour, (4) social support (unspecified), (5) social
reward, (6) goal-setting-behaviour, (7) action planning,
(8) review of behaviour goal, (9) social support (prac-
tical), (10) goal-setting (outcome), (11) review of out-
come goal, (12) information about health consequences,
(13) prompts/cues, (14) restructuring the physical envir-
onment, (15) adding objects to the environment and
(16) instruction on how to perform the behaviour.
Session overview
The intervention was designed to be delivered over three
to four sessions depending on the patient’s level of ad-
herence and desire for additional support (see Fig. 1).
The app was designed to guide the pharmacist in tailor-
ing the number and type of sessions. Adherence was re-
assessed at each follow-up session using MARS-5 [22]
and one item adapted from Lu et al. [23].
At session 1, an adherence assessment (BCT: problem
solving) was undertaken, guided by the app, to explore a
range of barriers to adherence that were identified as im-
portant in our previous research [11] such as knowledge,
routines, forgetfulness and motivation (see example in
Fig. 2). Each identified adherence problem was then
automatically linked to a range of potential solutions
that reflect specific BCTs (see example in Fig. 3). To-
gether, patients and pharmacists selected the most ap-
propriate solutions to address each of the identified
problems. All patients were also offered a medication
diary at session 1 to encourage them to self-monitor
their medication-taking behaviour and identify any in-
stances of non-adherence over the course of the inter-
vention period which they could then discuss with the
pharmacist at follow-up sessions.
At follow-up sessions, a review of the medication diary
was undertaken by the pharmacist and feedback given if
the diary was completed. Alternative (or additional) so-
lutions could be recommended if adherence had not im-
proved and/or if the patient requested more support.
The data recorded on the app were saved at the end of
each session and pharmacists could review this in ad-
vance of the next session. Space for recording brief notes
during or after the sessions was also available. Further
details of the intervention sessions and content can be
found in the study protocol [17].
Training package
The interactive 1-day training workshop included an
introduction to the study, study procedures (e.g. recruit-
ment), information on the intervention, video demon-
strations of the app, a practice session using the app and
role-play activities focusing on new skills required to de-
liver BCTs such as goal-setting and action planning. The
training workshops were audio-recorded with pharma-
cists’ permission and pharmacists completed a feedback
survey. These data will be analysed and reported as part
of a separate process evaluation.
Outcome data collection
Outcome data were collected at baseline/pre-session 1
(questionnaires administered by pharmacy staff), and
again at 6 months’ post-baseline (questionnaires admin-
istered by research team).
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Primary outcome
The primary outcome was medication adherence across
multiple medications. This was measured using two
methods which included both subjective and objective
measures. This multi-method approach is currently rec-
ommended due to the lack of a single gold standard
measure for medication adherence [30].
Medication possession ratio and daily polypharmacy
possession ratio
Using dispensing data obtained from participating com-
munity pharmacy PMR computer systems, the Medica-
tion Possession Ratio (MPR) and Daily Polypharmacy
Possession Ratio (DPPR) were calculated for each patient
[31, 32]. MPR is the most widely used measure of adher-
ence based on pharmacy dispensing data [32]. MPR can
be calculated by dividing the number of days of medica-
tion supply obtained in the observation window (minus
the number of days supplied in the last dispensing epi-
sode) by the number of days between the first and last
dispensing episode in the observation window [31]. At
least two dispensing instances in the observation window
are therefore required for the calculation of MPR. In the
current study, the MPR was capped at 1 (i.e. 100%) for
each medication and an average MPR (multiplied by 100
to give a %) for all regular medications calculated for
each patient. However, MPR may either over- or under-
estimate adherence to polypharmacy regimens, for ex-
ample, because it does not consider overlapping supplies
of medications [33]. The DPPR is a relatively new meas-
ure of adherence based on dispensing data, that aims to
overcome some of the limitations with MPR as it ‘…ac-
counts for the specificity of polypharmacy’ including
overlapping supplies [33]. The DPPR reflects the propor-
tion of time that multiple medications are available in
the observation window. This is calculated by looking at
each day in the observation window and considering
whether the patient has each regular medication avail-
able or not. The proportion of medicines available for
each day in the observation window is then summed and
divided by the number of days in the observation win-
dow to produce the DPPR (this is then multiplied by
100 to give a %).
The observation windows for assessment of both MPR
and DPPR in this study were the 6 months pre-session 1
(window 1) and 6months post-session 1 (window 2). For
the DPPR, accumulated unused oversupply of medicines
dispensed in the 6-month period before each observa-
tion window could be carried over into the observation
window. Data were collected for the 12 months pre-
Fig. 1 Overview of sessions and timings in the S-MAP intervention
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session 1 to facilitate this carryover into window 1.
DPPR and MPR were calculated using the statistical
programme R and AdhereR package [34]. MPR was cal-
culated using the CMA3 (Continuous Medication Avail-
ability) function in AdhereR [34] and DPPR was
calculated using code supplied by Dr. Samuel Alleman
(personal communication), who co-developed the
DPPR code for AdhereR (CMA-polypharmacy func-
tion). To ensure the code was functioning correctly,
manual calculations of both DPPR and MPR were
performed and comparisons made with the R
computations.
Only medications prescribed on a regular basis (> 3
months’ supply) were included. Medications that are
commonly recommended for short periods of time
and/or for symptomatic relief were excluded (e.g.
pain-relieving agents, laxatives, hypnotics, anxiolytics,
antihistamines). Medications that were prescribed with
‘when required’ or variable dosing directions (e.g. take
1 or 2 tablets daily) or formulations where dosing is
difficult to estimate (e.g. creams, insulin) were also
excluded. Medications with simple dosage changes
(e.g. increased from 2 to 4 mg strength) were in-
cluded; however, more complex switches such as
changes between combination products and individual
medications were excluded [33, 35].
Self-reported adherence
Self-reported adherence was measured using MARS-5
[22] and one item adapted from Lu et al. [23]. Permis-
sion for use of MARS-5 was granted by the developer
(Professor Robert Horne). At baseline, these measures
were initially administered by pharmacy staff as part of
the screening process; however, following the amend-
ments to screening procedures, these measures were ad-
ministered following recruitment (i.e. before session 1)
along with secondary outcome measures (see below).
Secondary outcomes
Secondary outcome measures included health-related
quality of life (HRQOL), measured using the EQ-5D-5L
questionnaire (UK version), and unplanned hospital ad-
missions, resulting in an overnight stay which was mea-
sured via a self-report tool developed specifically for the
purposes of this study. The EQ-5D-5L consists of two
sections: a five-item questionnaire and a visual analogue
scale (EQ-VAS) [36]. EQ-5D-5L utility index scores were
calculated using question responses and a mapping func-
tion developed by van Hout et al. [37] as recommended
currently by the UK National Institute for Health and
Care Excellence (NICE) [38]. Index scores less than 0
are described as being worse than death and a score of 1
indicates a state of perfect health. These measures were
Fig. 2 An example of an adherence assessment question in the S-MAP web application
Patton et al. Pilot and Feasibility Studies            (2021) 7:18 Page 7 of 21
administered at baseline (pre-session 1) by the pharma-
cist/trained pharmacy support staff and again at 6
months’ post-baseline (via postal questionnaire adminis-
tered by the research team). Patients were sent reminder
copies of the questionnaire and non-responders con-
tacted via telephone (where contact numbers were pro-
vided). Information on unplanned hospital admissions
was also cross-checked with GP-held records which
community pharmacists obtained via telephone from the
patient’s GP practice.
Data analysis
For all descriptive statistics (e.g. patient age, MPR,
MARS-5), the mean and standard deviation (SD) are
presented where data are approximately normally dis-
tributed, and the median and interquartile range (IQR)
reported where data are non-normally distributed. For
the dispensing data (MPR, DPPR), self-reported adher-
ence (MARS-5, Lu item) and HRQOL (EQ-5D-5L utility
index and EQ-VAS) scores pre- and post-session 1, con-
fidence intervals (95%) and effect sizes (r) are also pro-
vided. Effect sizes (r) have been presented to give an
indication of the magnitude of change between pre- and
post-session 1 scores [39]. An effect size (r) of ± 0.1 is
deemed to be a small effect size, ± 0.3 a medium effect
size and ± 0.5 a large effect size [40]. Due to the small
numbers of unplanned hospital admissions observed
during the study period, the total numbers of admissions
(and number of patients with admissions) have been pre-
sented. Patients were excluded from an outcome analysis
if they had missing data at pre- or post-session 1. Ana-
lysis was conducted using SPSS (IBM Corp. Released
2019. IBM SPSS Statistics for Windows, Version 26.0.
Armonk, NY: IBM Corp.)
Progression criteria
Explicit a priori progression criteria, published in the
study protocol paper [17], have been used to determine
whether to proceed to a larger c-RCT to assess the ef-
fectiveness of the enhanced S-MAP intervention [41].
Cut-off points were developed based on work published
by Borelli et al. [42], which indicates that high fidelity is
when ≥ 80% of the criteria are met (‘Stop’), medium fi-
delity is when 50% of the criteria are met (‘Amend’) and
low fidelity is when < 50% of the criteria are met (‘Stop’).
Data to support the decisions for progression criteria
concepts related to training and intervention fidelity, in-
cluding in-depth qualitative analyses, will be reported in
a separate process evaluation paper.
Fig. 3 An example of recommended solutions displayed for an identified adherence problem in the S-MAP web application
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Ethical approval, reporting and patient/public
involvement
The study was granted ethical approval by the Office of
Research Ethics Committees for Northern Ireland (REC
reference: 17/NI/0193) and the study protocol published
in advance [17]. This study has been reported in line
with the Consolidated Standards of Reporting Trials
(CONSORT) extension for reports of randomised pilot
and feasibility studies as recently recommended by Lan-
caster and Thabane [43]. A completed CONSORT
checklist can be found in Additional file 3. Two patients
and two community pharmacists from NI and London
formed part of a Patient and Public Involvement (PPI)
advisory group that provided advice to the research team
during the study.
Results
Pharmacy sampling, recruitment and retention
Twelve community pharmacies were recruited over a 3-
month period (April-June 2018), six from the five HSCT
areas in NI and one from each of the six selected CCGs
in London. From the 120 letters posted, 12 reply slips
expressing interest were returned [7 in NI, 5 in London;
overall response rate (letter) = 10%]. From those who
returned reply slips, eight pharmacies were recruited (3
in NI, 5 in London; overall recruitment rate (letter) =
7%). Reasons for non-participation/ineligibility from the
posted invitations included the lack of a suitable consult-
ation area (n = 1) and difficulty with arranging an initial
site visit (n = 1). No specific reason was provided by one
pharmacy and one reply slip was received after recruit-
ment targets were met. Pharmacies who did not return
reply slips were contacted via telephone until the re-
cruitment target of 12 was achieved. Seven non-
responding pharmacies in NI and 14 pharmacies in
London (total n = 21) from CCGs/HSCT areas where no
pharmacies had been recruited (including a range of dif-
ferent types of pharmacies) were contacted via tele-
phone. Six pharmacies in NI and 7 in London (total n =
13) expressed potential interest at this stage [overall re-
sponse rate (follow-up phone call) = 62%] and were sent
additional study information. Four further pharmacies
were recruited using this approach [3 in NI, 1 in
London; overall recruitment rate (follow-up phone call)
= 19%], thereby achieving the recruitment target. Rea-
sons for non-participation from the telephone follow-
ups included: insufficient time (n = 8), difficulties with
arranging locum cover (n = 1) and the need for head of-
fice to approve participation (n = 1). No specific reason
for non-participation was provided by one pharmacy
and six pharmacies were no longer required as recruit-
ment targets were met. At the end of the 12-month
study period, 11 of the 12 recruited pharmacies had been
retained. One pharmacy in London withdrew from the
study prior to the recruitment of patients due to insuffi-
cient time.
Pharmacy and staff characteristics
In NI, four pharmacies were independently owned (1-3
stores) and two were part of large chains (10+ stores).
NI pharmacies were located in areas with NI MDM
scores of 55, 176, 238, 342, 390, 431 (where 1 = most de-
prived area, 890 = least deprived area in NI) with two
pharmacies located in urban areas and four pharmacies
located in rural areas [19]. In London, five pharmacies
were independently owned (1-5 stores) and one was part
of a small chain (6-99 stores). London-based pharmacies
were located in areas with IMD decile scores of 2, 2, 5,
6, 9 and 9 (where 1 = most deprived area, 10 = least de-
prived area in London) [18] and were located in both
urban and suburban areas. Seven pharmacies had one
full-time equivalent (FTE) pharmacist staff member
working on an average weekday and three pharmacies
had two FTE pharmacists. One pharmacy had an add-
itional pharmacist working 1 day per week. Pharmacies
had a median of three (IQR: 2.3-4.0) FTE pharmacy sup-
port staff such as dispensing staff and medicines counter
assistants. On a typical weekday, the number of prescrip-
tions dispensed by pharmacies was 100-199 (n = 2), 200-
299 (n = 4), 300-399 (n = 3), 400-499 (n = 1), 600+ (n =
1). Data on staffing levels and prescription items were
not collected from the pharmacy that dropped out dur-
ing the study.
Fifteen community pharmacists, from the 12 recruited
pharmacy sites, took part in the study. Three sites had
two pharmacists participating at each site, and six sites
each had one support staff member (including four pre-
registration pharmacists) who assisted with study proce-
dures. Recruited pharmacists (n = 14) working in phar-
macies that were retained in the study had been
practising for a median of 15.5 years (IQR: 10.8-29.3).
Three pharmacists were pharmacy owners/proprietors,
seven were pharmacy managers and four were support/
second pharmacists. Nine pharmacists (64.3%) had
undertaken previous training in supporting patients with
medication adherence and two pharmacists were trained
as independent prescribers.
Pharmacy staff training
Recruited pharmacists attended training workshops in
August and September 2018. Seven pharmacists and one
support staff member (pre-registration pharmacist) from
the six pharmacy sites in NI attended the Belfast work-
shop. In London, six pharmacists from five of the phar-
macy sites attended the workshop. The training was
delivered over approximately 6 h by the same two mem-
bers of the research team (DP, EC). The online distance
learning Moodle® package was completed by five support
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staff members and one pharmacist in London and one
support pharmacist in NI who were unable to attend the
workshops. A member of the research team then visited
each pharmacy site to discuss any queries.
Patient screening, recruitment and retention
Patient screening and recruitment took place between
August 2018 and July 2019. Screening and recruitment
paperwork was completed for 104 patients in NI and for
36 patients in London. Information on screened patients,
including rates of non-adherence and recruitment rates,
can be found in Table 1. Feedback from pharmacists in
both NI and London during the study indicated that
they did not complete the screening paperwork for all of
the patients that they screened due to time constraints.
In total, using both screening approaches, 60 patients
were recruited into the study (36 in NI and 24 in
London). Pharmacies recruited between 0 and 10 pa-
tients each (median: 4; IQR: 1.3-9.8) with three pharma-
cies recruiting 10 patients and two pharmacies
recruiting 8 and 9 patients each. The mean age of re-
cruited patients was 69.4 (SD: ± 8.5; range: 50-85) years
and 37 participants (61.7%) were female. Additional in-
formation is provided in Table 1.
During the study, there were six patient withdrawals (3
in NI, 3 in London). Reasons included: death (n = 1), de-
mentia diagnosis (n = 1), patient withdrawal of consent (n
= 1) and failure to attend the initial S-MAP session (n =
3). In addition, seven patients did not have any primary
outcome data suitable for analysis (i.e. dispensing data or
self-report adherence data) (see ‘Primary outcomes’ sec-
tion). Therefore, 47 of the 60 recruited patients were
deemed to be retained in the study, giving an overall re-
tention rate of 78.3%. A participant flow diagram is pre-
sented in Fig. 4.
Intervention delivery
Ten of the 15 participating pharmacists, from nine phar-
macy sites, conducted sessions with 56 patients. In total,
155 sessions were delivered between September 2018
and October 2019 (99 in NI and 56 in London). Of
these, 118 (76.1%) sessions were conducted in the phar-
macy and 37 sessions were completed via telephone
(23.9%). The number of sessions attended by patients in-
cluded none (n = 4), one (n = 6), two (n = 4), three (n =
Table 1 Data from screening and recruitment paperwork completed by pharmacists
NI London Total
Initial screening proceduresa
Number of screening forms completed 74 24 98
Number of patients who completed the screening questionnaire (%) 52 (70.3) 22 (91.7) 74 (75.5)
Non-adherence rateb, % (number of eligible non-adherent patients) 46.2 (24); missing = 2 81.8 (18); missing = 0 56.8 (42); missing = 2
Recruitment ratec, % (number recruited) 62.5 (15) 77.8 (14) 69.0 (29)
Modified screening proceduresd
Number of screening forms completed 30 12 42
Non-adherence ratee, % (number of eligible non-adherent patients) 73.3 (22) 83.3 (10) 76.2 (32)
Recruitment ratec, % (number recruited) 95.5 (21) 100 (10) 96.9 (31)
Total number of screened patients (%) 104 (74.3) 36 (25.7) 140
Characteristics of recruited patients
Total number of patients recruited (%) 36 (60.0%) 24 (40.0%) 60
Mean age (± SD; range) 70.1 (± 8.5; 50-85);
missing = 0
68.3 (± 8.8; 50-84);
missing = 2
69.5 (± 8.6; 50-85);
missing = 2
Female, n (%) 23 (63.9) 14 (58.3) 37 (61.7)
Median number of prescribed medications (IQR; range) 7 (6-8; 4-13); missing = 1 8 (5-9; 3-15); missing = 1 7 (5.8-8.3; 3-15);
missing = 2
Median number of prescribed regular medications (IQR; range) 6 (5-7; 3-12); missing = 1 6 (5-7; 3-9); missing = 1 6 (5-7; 3-12);
missing = 2
Median number of prescribed non-regularf medications (IQR; range) 0 (0-1; 0-4); missing = 1 1 (0-3; 0-7); missing = 1 1 (0-2; 0-7);
missing = 2
aIncluded a screening questionnaire (Lu item and MARS-5) to assess adherence. Patients aged 65+ were eligible to take part
bNumber of eligible non-adherent patients from the total number who completed adherence screening questionnaire
cNumber of patients recruited from the total number of eligible non-adherent patients
dAdherence assessment completed using the PMR or via general discussions with the patients. Age limit lowered to 50+ years
eNumber of eligible non-adherent patients from the total number of patients screened
fIncludes medications used on a short-term basis or generally for symptomatic (when required) use
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43) and four (n = 3). Four patients brought along a fam-
ily member to the sessions and the GP was contacted on
only one recorded occasion to confirm the accuracy of
the patient’s prescribed medication list. The duration of
sessions was automatically recorded by the app upon
clicking the ‘complete’ button (Table 2). However,
some pharmacists reported that data were occasion-
ally entered retrospectively (e.g. following completion
of the session without the app or forgetting to save
the session). The recorded durations of some sessions
(Table 2) may therefore underestimate the true ses-
sion length.
The median number of days between sessions 1 and 2
was 30.5 days (n = 50; IQR, 15.0-69.3; recommended, 7-
14), between sessions 2 and 3 was 60 days (n = 46; IQR,
48.5-88.5; recommended, 42-56) and between sessions 3
and 4 was 49 days (n = 3; IQR, unable to calculate; rec-
ommended, 42-56).
During session 1, an adherence assessment was con-
ducted for each patient (n = 56). Barriers to adherence were
Fig. 4 Participant flow diagram for the S-MAP study. 1One patient was ineligible for two reasons: prescribed medications for dementia and
adherent based on PMR data/discussions; 2Reasons included non-completion of the baseline questionnaire, non-completion of 6-month follow-
up questionnaire, unable to collect dispensing data due to COVID-19 pandemic and/or dispensing data not suitable for analysis due to
instalment (weekly) dispensing
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identified during this session for all but one patient (who
chose to withdraw from the study following the first ses-
sion). A median of two adherence barriers was identified
per patient (IQR, 2-4). A wide range of barriers to adher-
ence were identified including knowledge issues (n = 23),
daily routine/organisation issues (n = 17), practical barriers
(n = 12), lack of support from others (n = 5), belief-based
barriers (n = 32) and motivational barriers (n = 8). Further
information on the types of barriers identified during the
assessment are presented in Table 3. Pharmacists were also
given the opportunity to record any additional barriers that
were not listed as options on the app. All additional barriers
recorded in this section could have been categorised into
barriers already listed on the app (n = 3).
Following identification of barriers, pharmacists deliv-
ered a wide range of tailored adherence solutions as rec-
ommended by the app. One pharmacist who conducted
a session with only one patient did not identify any ad-
herence barriers and so did not deliver any solutions.
Therefore, nine pharmacists delivered solutions to 55
patients. In total, 265 solutions were delivered during
the sessions with a median of five solutions per patient
(IQR: 2-7). Of these, 129 were practical/social support-
based solutions, with a median of two per patient (IQR:
1-3) and 57 were belief/motivation/goal-based solutions,
with a median of one per patient (IQR: 0-2). The major-
ity of solutions (n = 244; 92%) were delivered at session
1. Further details of the types of solutions delivered dur-
ing the sessions are detailed in Table 4.
Primary and secondary outcomes
Six-month follow-up data for the primary and secondary
outcomes were collected between March 2019 and
March 2020. The proportion of missing data across both
primary and secondary outcome measures was 30.1%
(Additional file 4).
Primary outcomes: adherence (MPR, DPPR and self-report)
Full dispensing records covering the six months pre-
and post-session 1 were collected for 52 patients. Full
dispensing records were not available for the six patient
withdrawals noted previously and records could not be
collected for two patients due to contextual issues in the
community pharmacy setting (i.e. the COVID-19 pan-
demic that arose during the final period of data collec-
tion). From the 52 records obtained, 44 patients (73.3%)
had dispensing data that were suitable for analysis. Dis-
pensing data were not suitable for analysis for six pa-
tients who had medications dispensed on a weekly basis.
As pharmacies have different processes for prescription
ordering and the production of dispensing labels/records
for these types of patients, these were not deemed to be
an accurate representation of the patient’s medication
possession and were therefore excluded. Two patients
were excluded as they had fewer than two medications
suitable for analysis.
Baseline questionnaire data, including self-reported ad-
herence data (Lu item, MARS-5), were collected for 51
of the 60 recruited patients. Pharmacy staff did not ad-
minister baseline questionnaires to nine recruited pa-
tients. Six-month follow-up questionnaires were mailed
by the research team to 54 of the 60 recruited patients
(six patients withdrew from the study prior to this
follow-up period). In total, 43 out of the 54 follow-up
questionnaires were returned (i.e. 79.6% response rate).
Thirty-seven patients (61.7%) had both baseline and 6-
month follow-up self-reported adherence data suitable
for analysis.
Median scores and effect sizes (r) for DPPR, MPR and
self-reported adherence measures (Lu item, MARS-5) in
the 6-months pre- and 6-months post-session 1 are pre-
sented in Table 5. The median number of medications
eligible for the DPPR and MPR calculations per patient
was five (IQR: 4-6).
Secondary outcome: quality of life (EQ-5D-5L)
Thirty-five patients completed the EQ-5D-5L in both
the pre- and post-session 1 questionnaire. Median scores
and effect sizes (r) for the EQ-5D-5L utility index and
EQ-VAS in the 6-months pre- and 6-months post-
session 1 are presented in Table 5.
Secondary outcome: Unplanned hospitalisations
Self-reported and GP-reported pre- and post-session 1
data on unplanned hospitalisations were available for 23
and 47 patients, respectively. Full 6-month pre- and
Table 2 The duration of sessions in the S-MAP intervention (recorded by the app)
Session number Location N (missinga) Median session duration in mm:ssb(IQR) Range
1 Pharmacy 53 (3) 15:18 (08:41-25:37) 03:24-52:21
2 Pharmacy 49 (1) 07:44 (02:40-16:48) 00:45-38:25
3 Telephone 36 (1) 01:37 (00:46-04:01) 00:22-21:08
Pharmacy 9 (0) 11:44 (08:01-15:53) 02:27-30:48
4 Pharmacy 3 (0) 03:23 (NAc) 01:52-20:39
aError with time recording—data excluded
bMinutes: seconds
cUnable to calculate Interquartile range (IQR) due to low numbers
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post-session 1 data were not available for the six patients
who withdrew, so these were excluded from this ana-
lysis. GP-reported hospitalisations data could not be col-
lected for one pharmacy site (n = 7 patients) due to the
COVID-19 pandemic.
In the 6 months’ pre-session 1, there were four self-
reported unplanned hospital admissions (from three pa-
tients) and six GP-reported admissions (from four pa-
tients). In the 6 months’ post-session 1, there were two
self-reported admissions (from two patients) and one
GP-reported admission.
Progression criteria
Following assessment of the a priori progression criteria,
nine concepts met the ‘Go’ criterion (see Table 6) and
three concepts (‘Patient recruitment’, ‘Patient retention’
and ‘Missing data’) met the ‘Amend’ criteria. None of
the decision criteria indicated that a further evaluation
Table 3 Barriers to adherence identified during the adherence assessment conducted during session 1
Barriers identified Number of patients
Knowledge (TDF domain: Knowledge)
Knowledge issues 23
Routine/organisation
(TDF domains: Nature of the behaviours; behavioural regulation; memory, attention and decision processes)
Difficulties ordering supplies of medications 11
No clear routine for taking medications 9
Total number of patients with routine/organisation barriersa 17
Forgetting (TDF domains: Memory, attention and decision-making processes; environmental context and resources; behavioural regulation)
Occasional forgetfulness 30
Frequent forgetfulness 6
Forgets when away from home 6
Total number of patients with forgetting barriersa 39
Practical difficulties (TDF domain: Environmental context and resources)
Dexterity/administration issue 3
Packaging/formulation issue 6
Unable to read/understand labels 2
Difficulty swallowing 5
Regimen too complex 1
Total number of patients with practical barriersa 12
Social support from others (TDF domain: Social influences)
More support required 5
Beliefs/intentional non-adherence (TDF domains: Beliefs about consequences)
Reasons for missed doses
General concerns about medications 10
Concerns about generic medicines 1
Experiencing side effects 11
Lack of symptoms 5
Unaware of health consequences 7
Worried about side effects 9
Uncertain of benefits 11
Total number of patients who reported missed dosesa 32
Motivation (TDF domain: Motivation and goals)
Inappropriate prioritisation 4
General lack of motivation for taking medicines 4
Total number of patients with motivation barriersa 8
aPatients may have had multiple different types of barriers identified in this category
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Table 4 Adherence solutions delivered during sessions as part of the S-MAP intervention (as recorded by pharmacists on the app)
Adherence solutiona Behaviour change
techniques (BCT) [29]
Number of pharmacists who
delivered the solutionb
Number of patients who
received the solutionc
Self-monitoring solutions
Medication diary accepted Self-monitoring of behaviour 9 31
Travel-size version of diary supplied 1 1








Store medicines in visually prominent place Restructuring the physical
environment
7 25
Large print labels 1 1
Link medications to common routine Prompts/cues 8 25
Reminder in own travel itinerary 2 3
Mobile phone reminders 4 6
Mark-reorder dates on diary Prompts/cues; self-
monitoring
1 4
Synchronise medication supply with GP Social support (practical) 4 7
Practical support—family/friends 3 4
Pharmacy help with prescription re-ordering 4 9
Pharmacy to collect prescriptions 3 7
Pharmacy delivery service 3 3
Pharmacy supplied MDS Adding objects to the
environment
2 3
Purchase pill reminder box 6 7
Alternative packaging 4 4
Physical aids 0 0
Swallowing tips Instruction on how to
perform the behaviour
4 5
Simple advice to improve administration 3 3
Discuss options with prescriber NA 5 13
Number of patients who received practical/social support solutions 46/55




Voicing concerns about medicines leaflet Information about health
consequencesd
5 11
Generic medicines leaflet 0 0
Two-way conversation about benefits of adherence/consequences
of non-adherence
6 18
Strategies to manage mild side effects NA 4 8
Set positive health goal Goal setting (outcome) 1 2
Set adherence goal Goal setting (behaviour) 3 8
Develop action plan Action planning 3 8
Review positive health goal Review outcome goal 0 0
Review adherence goal Review behaviour goal 2 2
Number of patients who received belief/motivation/goal solutions 30/55
Number of pharmacists who delivered belief/motivation/goal solutions 8/9
aSome solutions were repeated/delivered again at follow-up sessions but these have only been counted once
bNine pharmacists delivered solutions to patients during sessions
cFifty-five patients had barriers identified and solutions delivered
dIncluded information on the importance of raising concerns, managing side effects, the importance of taking medicines as prescribed and only stopping
medicines after consulting the prescriber
Patton et al. Pilot and Feasibility Studies            (2021) 7:18 Page 14 of 21
of S-MAP should not proceed. The concept, ‘Acceptabil-
ity of intervention to pharmacists’, was not assessed for
the purposes of progression decision-making. The de-
tailed qualitative feedback interviews with community
pharmacists that were intended to be used for this pro-
gression concept did not ask participants for an overall
binary evaluation of the intervention (is the intervention
acceptable?—yes or no). Alternatively, these interviews
focused on exploring the degree of acceptability of spe-
cific components of the S-MAP intervention (e.g. the
app, the medication diary, barrier identification, selecting
solutions). The qualitative data on intervention accept-
ability will be reported in-depth as part of the linked
process evaluation and published separately. ‘Fidelity of
pharmacist training package receipt’ was assessed solely
using a post-workshop feedback survey. Data obtained
from audio-recordings of pharmacist workshops did not
contribute to the decision-making process for this con-
cept, as was originally planned, due to the low quality of
audio-recordings which did not consistently pick up
each individual voice, therefore the data required for the
analysis were not available.
Discussion
This non-randomised pilot study explored approaches to
sampling, screening and recruitment of community
pharmacies and older patients in two regions in the UK.
It included preliminary testing of a novel web-
application to guide the delivery of a tailored theory-
based intervention to improve adherence to multiple
medications. The feasibility of collecting data for a range
of outcome measures including medication adherence,
HRQOL and unplanned hospital admissions was also ex-
plored. This research will advance the existing literature
by helping to address evidence gaps identified in the re-
cent Cochrane review of adherence interventions
delivered to older people prescribed multiple medicines
that noted a lack of tailored interventions in this area
[1].
Sampling, screening and recruitment procedures
The procedures for identifying and recruiting pharma-
cies in this pilot study were successful with 12 pharma-
cies recruited within the allocated timeframe. One
central London pharmacy withdrew as staff had insuffi-
cient time to dedicate to the study. In a future trial, it
will be important to ensure that pharmacies have a real-
istic understanding of time required for intervention ac-
tivities and adequate resources and staffing levels to
participate.
Challenges were experienced with patient recruitment
during the study which led to amendments to study pro-
cedures. The removal of the screening questionnaire and
reduction of the eligibility age limit from 65 to 50 years
increased eligibility rates from 56.8 to 76.2% and recruit-
ment rates from 69.0 to 96.9%. Despite these improve-
ments, the maximum target of 120 patients was not met.
However, the minimum target, based on the a priori
progression criteria, was met, indicating that further
amendments to the recruitment protocol (e.g. additional
support for patient recruitment such as using research
nurses) will be required for a future cRCT. Due to the
time constraints in community pharmacies, the paper-
work and procedures associated with recruitment was
burdensome for pharmacists, who often have limited or
no experience in taking part in clinical trials. This re-
flects findings from other studies conducted in commu-
nity pharmacies [35, 44, 45]. To enhance recruitment
rates in a future trial, additional external support for
pharmacists may be required, for example, support from
infrastructure such as Clinical Research Network (CRN)
staff [46].










for post-session 1 median
Za Effect
size (r)b
Primary outcome: dispensing data measures (DPPR, MPR)
DPPR (%) 44 85.2 (72.0-96.7) 73.9-92.9 93.8 (84.8-97.8) 86.8-96.7 −3.80 −0.41
MPR (%) 44 93.8 (82.8-100.0) 88.9-97.5 94.6 (87.8-97.8) 89.7-97.5 −1.28 −0.14
Primary outcome: self-reported adherence
Lu item (%) 36 80 (60-80) 60-80 100 (80-100) 80-100 −3.45 −0.41
MARS-5 total 25 22 (20-23.5) 21-23 24 (24-25) 24-25 −3.12 −0.44
Secondary outcome: EQ-5D-5L
EQ-5D-5L- Utility index 30 0.73 (0.52-0.84) 0.53-0.80 0.74 (0.58-0.84) 0.65-0.77 −0.91 −0.12
EQ-5D-5L-VAS 35 75 (50-83) 60-80 75 (60-85) 65-80 −0.12 −0.01
Key: DPPR daily polypharmacy possession ratio; MARS-5 Medication Adherence Report Scale; MPR medication possession ratio; IQR interquartile range
aTest statistic for Wilcoxon signed-rank test
bEffect size (r) calculated using r = Z/√N; where Z is the z score for the Wilcoxon signed-rank test and N is the total number of observations. −0.1 indicates a small
effect size, −0.3 indicates a medium effect size and −0.5 indicates a large effect size



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Patton et al. Pilot and Feasibility Studies            (2021) 7:18 Page 17 of 21
Although pharmacists were advised initially to screen
all older patients, a selective approach may be more
pragmatic given the time restrictions in this setting. In
the modified study procedures, pharmacists used a more
targeted strategy and identified non-adherent patients
based on their PMR dispensing data or informal discus-
sions with patients. A review of 190 RCTs of adherence
interventions, conducted in a range of settings, found
that ‘the inclusion of nonadherent patients was the sin-
gle feature significantly associated with effective adher-
ence interventions’ [47]. It is therefore important that
practical and cost-effective approaches to identify non-
adherent patients are adopted in future research studies.
The target age in this study was reduced from 65 to
50 years based on feedback from participating pharma-
cists. Addressing non-adherence prior to reaching older
age may have benefits that last into later life, particularly
if good adherence is established in the early stages fol-
lowing the diagnosis of long-term conditions. UK-based
ageing charities (e.g. AgeUK) offer their services to pa-
tients aged ≥ 50 years, which also supported lowering of
the age limit in the study [48]. To ensure optimum ad-
herence in the later stages of life, it may be prudent for
future trials to consider targeting a wider group of pa-
tients with long-term conditions.
Intervention delivery
The recommended minimum number of sessions was
three; however, 10 patients received only one or two ses-
sions and four patients did not attend any sessions. Most
solutions were delivered during session 1 which suggests
that a smaller number of sessions (e.g. two) may be suffi-
cient to deliver this type of intervention. The interven-
tion protocol also recommended that session 2 should
take place 1-2 weeks after session 1. Based on the find-
ings from this study, it appears that a longer time period
that coincides with prescription collection frequency
(e.g. 4-8 weeks) may be more appropriate.
Pharmacists identified a wide range of adherence bar-
riers during the sessions and reported the delivery of a
variety of solutions tailored to these underlying barriers.
All barriers listed on the app were identified in at least
one patient and no additional barriers were identified.
Furthermore, all but three solutions (physical aids, re-
view positive health goal and generic medicines leaflet)
in the intervention were delivered to at least one patient.
These findings highlight the relevance and comprehen-
siveness of the app content. This also supports the utility
of the TDF and BCT mapping approach that was used
to guide intervention development [11, 15]. In compar-
ing the types of solutions delivered, a larger number of
practical/social support solutions were delivered (n =
129) in contrast with motivation/goal-based solutions (n
= 57); this may be explained by community pharmacists’
lack of experience in delivering motivational techniques.
This reflects findings from previous research that identi-
fied a lack of training in these techniques as a potential
barrier to delivering this type of adherence intervention
[49]. Although training on motivational and goal-based
techniques was provided during the workshops, further
training and support (e.g. structured ongoing support
during intervention delivery) will be required in future
research studies.
Outcome data collection
This pilot study has identified potential issues with miss-
ing data that will need to be addressed in advance of a
definitive cRCT. In future research, patients who are dis-
pensed instalment prescriptions should be excluded at
baseline to help avoid this type of missing data. Given
the low numbers of patients with self-reported hospital-
isation data (n = 23) in comparison to data collected
from GP records (n = 47), collecting data solely from GP
records or administrative databases may be a better op-
tion. Some patients appeared to experience difficulties
with completing the MARS-5 section of the adherence
questionnaire. Strategies to enhance completion rates
will need to be considered for the future (e.g. more sup-
port from researchers). There were also issues with the
administration of baseline questionnaires, which was a
procedure that was delegated to pharmacy staff. To min-
imise missing data, this process should be managed by
external research support (e.g. CRN staff).
Strengths and limitations
This study involved the systematic development and
testing of a theory-based intervention, in line with UK
MRC guidance for complex interventions [9], to enable
community pharmacists to improve adherence to mul-
tiple medications in older adults. The use of a priori pro-
gression criteria in this study has also allowed for a
transparent and impartial decision-making process on
whether to proceed to a cRCT.
The study was conducted across two jurisdictions.
However, it is limited by the small sample size and lack
of control group, thus the presented outcome data
should be interpreted with caution. No large community
pharmacy chains were recruited in London (due to the
time required to obtain head office approvals) and phar-
macies in NI were located mainly in more deprived
areas. Future research should seek to include more phar-
macies to enhance representativeness of the wide diver-
sity of pharmacy settings in the UK. The 12-month
follow-up time point was removed from this study due
to recruitment delays. Future research should therefore
seek to include a longer follow-up period for outcome
data collection.
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As noted previously, three of the assessed concepts re-
lated to patient recruitment, patient retention and miss-
ing data met the ‘Amend’ progression criteria as
opposed to the ‘Go’ progression criteria’. Some of the
strategies discussed above will be important to consider
as strategies to increase recruitment and retention rates
and reduce the amount of missing data. Based on the
available data, the research should progress to a cRCT in
the next phase following modifications. An embedded
(i.e. internal) pilot study may be required to assess
changes that will need to be made to the study proce-
dures (e.g. patient recruitment) and the intervention (e.g.
app changes), as well as assessing procedures not tested
in the current study such as randomisation.
Conclusions
The results from this non-randomised pilot study sup-
port the future testing of the S-MAP intervention in
community pharmacies in a definitive trial with modifi-
cations required to enhance patient recruitment, reten-
tion and data collection procedures. This study also
highlights the utility of the theoretical approach that
guided intervention design as it has resulted in an inter-
vention that can identify a wide range of underlying rea-
sons for non-adherence and lead to the delivery of
tailored solutions. Future research will involve a cRCT
to explore the effectiveness of the S-MAP intervention
in improving adherence to multiple medications in older
adults.
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